Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 8/20 | 0.80 |
| ▸ | EGFR | P00533 | 6/20 | 0.56 |
| ▸ | ABL1 | P00519 | 5/20 | 0.56 |
| ▸ | ABL2 | P42684 | 5/20 | 0.56 |
| ▸ | KDR | P35968 | 4/20 | 0.56 |
| ▸ | CDK1 | P06493 | 3/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 5/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30150810 | 1.00 | SRC (0.80) | SRCEGFRABL1ABL2KDR | |
| SCHEMBL30150807 | 1.00 | SRC (0.80) | SRCEGFRABL1ABL2KDR | |
| SCHEMBL22086067 | 0.94 | SRC (0.78) | SRCEGFRABL1ABL2KDR | |
| SCHEMBL22604442 | 0.89 | SRC (1.00) | SRCEGFRABL1ABL2KDR | |
| SCHEMBL22086070 | 0.87 | SRC (0.84) | SRCEGFRABL1ABL2KDR | |
| SCHEMBL22084743 | 0.87 | SRC (0.84) | SRCEGFRABL1ABL2KDR | |
| SCHEMBL22084757 | 0.82 | SRC (0.55) | SRCEGFRABL1ABL2KDR | |
| SCHEMBL20911785 | 0.82 | SRC (0.84) | SRCEGFRABL1ABL2KDR | |
| SCHEMBL20351621 | 0.81 | SRC (0.82) | SRCEGFRABL1ABL2KDR | |
| SCHEMBL22084756 | 0.80 | SRC (0.52) | SRCEGFRABL1ABL2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230055250-A1 | MAP4K4 INHIBITORS | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2023-02-23 | — | — | US | disclosed |
| WO-2020115481-A1 | MAP4K4 INHIBITORS | IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE (GB) | 2020-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230055250-A1 | MAP4K4 INHIBITORS | MAP4K4, MAP4K5, MAP4K1 | SRC 739/4885EGFR 1053/4885ABL1 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.